World News – AU – RLI Corp Just Beat Revenue Expectations: Here’s What Analysts Think Will Happen Next


As you may know RLI Corp (NYSE: RLI) just launched its latest quarterly results with very solid numbers It was a solid earnings report, with revenue and statutory profit Per Share (EPS) both very strong Revenue was 13% higher than analysts forecast at US $ 263 million, while EPS was US $ 093 analyst models beating 629% Analysts typically update their forecasts with each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are new concerns to take into account We have assembled the most recent statutory forecasts to see if analysts have changed their earnings models, following these results

Based on the latest results, the current consensus of RLI’s five analysts is for revenue of US $ 9958m in 2021, which would reflect a modest 5% increase in sales over the past 12 months. Statutory earnings per share expected to decline 39% to USD 271 in the same period Yet, before the latest results, analysts had forecast revenue of USD 977 million and earnings per share (EPS) of USD 262 in 2021 Analysts appear to have become more bullish on activity, judging by their new earnings per share estimates

No major changes have been made to the consensus price target of $ 98.50, suggesting that improving earnings per share outlook is not sufficient to have a positive long-term impact on the valuation of action This is not the only conclusion we can draw from this data, however, as some investors also like to factor in the spread in estimates when evaluating analysts’ price targets. Currently, the most bullish analyst values ​​the RLI at US $ 110 per share, while the most bearish the price at US $ 8700 Yet with such a narrow range of estimates, it suggests that analysts have a pretty good idea of ​​what they think the company is worth

Now looking at the big picture, one of the ways we can understand these forecasts is to see how they stack up against estimates of past performance and industry growth. It is clear from the latest estimates that the growth rate of RLI is expected to accelerate significantly, with the forecast 5 revenue growth of 5% significantly faster than its historic growth of 37% pune over the past five years. Other similar companies in the industry (covered by analysts) are also expected to grow their revenues by 48% per year The RLI is expected to grow at roughly the same rate as its industry, so it’s not clear we can draw any conclusions of its growth compared to its competitors

More important here is that analysts have updated their earnings per share estimates, suggesting that there has been a marked increase in optimism about the RLI following these results. They also reconfirmed their revenue estimates, with the company forecasting growth at about the same rate as the industry as a whole. There has been no real change in the consensus price target, which suggests that the intrinsic value of the business has not undergone any major changes with the latest estimates

That said, the company’s long-term earnings trajectory is much bigger than next year.At Simply Wall St, we have a full range of analyst estimates for RLI through 2022, and you can consult them for free on our platform here

Before taking the next step, you should know the 2 warning signs of RLI that we have discovered

This Simply Wall St article is general in nature It does not constitute a recommendation to buy or sell shares, and does not take into account your goals or your financial situation We aim to provide you with a focused analysis long term based on fundamental data Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative information Simply Wall St does not have any position in the mentioned stocks Do you have any comments on this article? Concerned about the content? Contact us directly You can also send an email to the editorial team @ Simplywallstcom

Individual investors have never been so worried about a US stock market crash This counterintuitive reaction is due to investor sentiment being a contrarian indicator Historical data on investor beliefs about probabilities of crashes come from Yale University finance professor (and Nobel Laureate) Robert Shiller

Kala Pharmaceuticals slipped Tuesday even after biopharmacy said the Food and Drug Administration approved its short-term treatment for signs and symptoms of dry eye Kala Pharmaceuticals said Eysuvis is the first prescription treatment approved specifically for the short-term treatment of chronic and episodic disease that affects tears and the ocular surface The FDA has approved Eysuvis based on the results of four clinical trials, including three Phase 3 trials and one Phase 2 trial, the company said

Individual retirement accounts and 401 (k) plans often impose penalties if you withdraw money from a retirement account too early or too late There is usually an early withdrawal penalty if you make a withdrawal before age 59 1/2 and a penalty for not receiving annual distributions after age 72 Here’s a look at the 401 (k) and IRA penalties you won’t have to pay this year

New Supreme Court Justice Could Help Kill Health Care Law What if you trust it?

The relentless defeat of everyone who bet against Elon Musk and Tesla’s stock has been well told But what about the big short sellers wins this year?

Apple has been an American success story on several occasions with the Mac, iPod, iPhone and other inventions But is Apple stock a buy now? Here’s what his stock chart and results show

If you’ve been following me for a very long time, you probably already know that I have long (for years) labeled Lisa Su « The best CEO » in the semiconductor industry If you know how much I think of Jensen Huang from Nvidia (Lisa Su’s cousin), we understand the level of admiration the statement reveals Advanced Micro Devices has reached definitive agreement to acquire Xilinx in all-stock transaction valued at $ 35 billion, or approximately $ 143 per share

There is still time to benefit from the 2020 IRA contribution limits And there is a good chance that you have not yet put the maximum allowed

Hasso Plattner, president and co-founder of SAP, on Monday bought shares worth nearly $ 300 million in the German software company after a one-time price drop in a generation triggered when management abandoned its profit targets The 76-year-old billionaire bought shares worth € 2,485 million ($ 294 million) at an average price of € 101, according to a regulatory brief released on Tuesday SAP shares fell 20% after CEO Christian Klein abandoned his « ambition » of steady growth in profit margins until 2023 and lowered the outlook for this year due to the impact of the coronavirus pandemic

When looking for the best artificial intelligence stocks to buy, identify companies that use AI technology to improve their products or gain a strategic advantage, such as Microsoft, Netflix, and Nvidia

(Bloomberg) – Sheldon Adelson’s Las Vegas Sands Corp is exploring selling its Las Vegas casinos, according to people with knowledge of the matter, a move that would leave the mogul focused on Asia and mark his exit, for the moment, from the US gaming industry’s largest casino company in the world, Sands is working with an advisor to generate interest at the Venetian Resort Las Vegas, the Palazzo and the Sands Expo Convention Center, which together could gross $ 6 billion. dollars or more, said those who asked not to be identified because discussions are private The properties are all connected along the city’s famous strip A representative from Las Vegas Sands has confirmed that it is in the early stages of discussions about a sale and nothing has been finalizedA sale would focus Sands’ casino portfolio entirely in Macau and Singapore, two of the biggest casino markets for Adelson, who ranks among the richest people in the world, with an estimated fortune of $ 29.7 billion The US was already a small portion of its shrinking business, accounting for less than 15% of sales last year « The growing insignificance of the US market explains why Las Vegas Sands is looking to unload its US properties, » said Ben Lee , Managing Partner of Macau-based IGamiX « That’s 15% of revenue but 80% of regulatory pain and burden » A recovery in Asia helped improve Sands’ operating results in the third quarter, Adelson said on an earnings call last week In Singapore, Marina Bay Sands had a profitable quarter as operations gradually resumed at the resort over the summer Money from a sale could allow the company to fund further development opportunities Sands has abandoned competing to build a casino in Japan earlier this year due to conditions described as unfavorable by executives Adelson, 87, has expressed interest in building in New York City, an opportunity that may present itself next year rose 12% after-hours trading on Monday after Bloomberg broke news of the deal Shares had closed 31% to $ 49 13 With the global pandemic creating uncertainty in the Las Vegas convention sector and an implicit price for properties with 12 times earnings before interest, taxes, depreciation and amortization, a deal could make sense, wrote Ben Chaiken, Credit Suisse analyst, note of research Monday night He added the caveat that it’s not clear who would buy the casinos Adelson is president, CEO and majority shareholder of Las Vegas Sands, which has a market value of $ 37.5 billion Macau casinos, the world’s largest gaming market, generated 63% of the company’s $ 13 billion in revenue last year, before the Covid-19 pandemic devastated the casino industry as it has other businesses where people congregate in large numbers, such as cinemas, concerts, and restaurants Singapore finished second with 22% Sands is growing in both regions, with Macau alone slated for $ 2 billion in spending What Bloomberg Intelligence says « The possible sale of its Las Vegas assets for $ 6 billion could fund these projects Asians, while $ 6 billion of existing cash would be enough to keep operations idle for 17 months China’s lifting of visa restrictions should benefit Sands in Macau « Brian Egger, Senior Gaming and Accommodation Analyst in Macau , after China gradually lifted travel restrictions and formed a travel bubble with the gaming hub, Macau’s recovery from Covid-19 fringes has been slow Visitor arrivals from mainland China over the week’s holiday China’s gold in early October fell 84% from the previous year However, there are signs that players are starting to return in volu me as visa backlog clears Adelson would cash in Vegas would come on city time « We’re seeing an increase in the number of real tourists on the ground in Macau, » Lee said « The profile of Chinese tourists is dominated by young people women and families – mainlanders taking advantage of the cheap accommodation on offer ”(Updates with analyst comments and Macau context from fifth paragraph) For more articles like this please visit us at bloomberg now to stay ahead with the most trusted source of business news © 2020 Bloomberg LP

Interest rates are extremely low, but returns of up to 10% are still available on the US stock market Risk is often part of the package

Raytheon posted mixed results in the third quarter as the collapse of global air transport hit its airline business hard

The chip industry consolidation dance continued this morning as AMD struck a deal to buy Xilinx for $ 35 billion, giving the company access to a wide range of Dedicated Workloads CEO Lisa Su believes acquisition will help her company become the leader in high-performance chips

More than a third of married or married couples say money is the most stressful in their relationships, according to a 2018 survey of more than 1,400 Americans by The Harris Poll on behalf of Ally Bank For some, money problems could lead the couple to go from marital bliss to divorce court « We all know that money is a major source of (marital) conflict, » says Dan Hill, Certified Financial Planner and President of Hill Wealth Strategies in Richmond, Virginia

It all depends on the thread The US Presidential elections are just a week away, and polls showing Biden has an advantage over President Trump, investors are bracing Oppenheimer’s chief investment strategist John Stoltzfus points out that last week, stocks went out of balance as investors rebalanced their portfolios, turning and adding additional exposure to value stocks « while others took profits in growth stocks that had previously risen significantly by compared to what could be a higher capital earnings and other taxes next year ”, in case Democrats win, Stoltzfus emphasizing that the wait for an effective COVID-19 vaccine is behind the widening investor appetite for stocks argues that this renewed appetite « improves the attractiveness of value stocks » Going forward, the strategist notes the efforts of the Federal Reserve « highlight the arguments for economic recovery and resilience and potential of stock markets here « Although a ‘blue wave’ is seen as a potential risk, Stoltzfus believes that this outcome is highly unlikely and that maintaining shared control should alleviate market concerns. Stoltzfus outlook, our attention has turned to three stocks according to Oppenheimer analysts, which could rise by at least 70% in the coming year Browsing through the tickers in the TipRanks database, we found that each enjoys a consensus Strong Buy rating from the broader analyst community Chromadex (CDXC) Focused on improving the way people aging, Chromadex operates as an integrated, science-based nutraceutical company Following a recent read of the data, Oppenheimer believes the time is right to get on board On October 6, the CDXC released the results of the Phase 2 study evaluating a nutritional protocol that includes its product Nicotinamide Riboside (NR) as well as the current standard of care in mild to moderate COVID-19 patients It should be noted that the study included around 100 patients and was conducted in partnership with ScandiBio Therapeutics, at a research hospital in Istanbul, Turkey Based on the data, patients receiving the NR plus standard of care combination saw 29% reduction in recovery time (66 days vs. 93 days) These findings add to existing research on NR, including 11 published clinical studies and more in progress Management Says Phase 3 Study to Start Soon Weighing Oppenheimer, 5-star analyst Brian Nagel commented, “For a while we recommended CDXC as a decidedly compelling, albeit speculative, investment game within specialized consumers We interpret [the] news as further indication that ChromaDex is continuing its tremendous and admirable effort to fully understand the science behind NR and its namesake product TruNiagen “Going forward, Nagel believes that the consumer audience is on the verge of s. expand “We are increasingly optimistic that a wave of NR-focused research from ChromaDex and its partners continues to develop and management is working to reinforce an effective marketing message that the mass market demand for NR and TruNiagen will rise, unlocking significant financial and operational levels of CDXC, « he explained To this end, Nagel gives CDXC an outperformance rating (ie Buy) with a price target of $ 9 If the target is met, a gain of 12 months in the form of a 90% could be in store (To see Nagel’s track record, click here) It’s not often that analysts all agree on a stock, so when this happens, take note CDXC’s Strong Buy consensus rating is based on a unanimous consensus of 3 buys The stock is $ 7 The average price target of 67 suggests a 61% rise from the current price of The $ 4.70 share (See CDXC stock analysis on TipRanks) Apellis Pharmaceuticals (APLS) Next, we have Apellis Pharmaceuticals, which is developing innovative therapies that target complement-mediated diseases With a solid setup emerging for 2021, Oppenheimer Beats the Table on Health Name APLS recently provided an update on its pipeline, including its systemic C3 inhibitor pegcetacoplan, which will target C3G / IC-MPGN and ALS 5-star analyst Justin Kim, who covers APLS for Oppenheimer, points out that C3G and IC-MPGN reflect a significant opportunity for systemic inhibition of C3, based on evidence that supports role of complement activation and depositionEven with the “suboptimal response” of a major factor D inhibitor, the analyst is optimistic about the C3 approach, “which could demonstrate more potent and broader inhibition of the cascade.” It should be noted that ‘An open label phase 2 study, enrolling up to 12 patients, was recently launched In addition to this, given that Alexion’s C5 approach is being explored in an ongoing Phase 3 ALS program, Kim has high hopes for this indication « The phase 2 study of the SPLA having recruited approximately 200 patients, the company estimates that the study could allow the registration At a potential case rate of around 5 / 100,000 in the US, ALS (and neurology) may reflect the greater longer-term opportunity for the systemic C3 pipeline, in line with Alexion’s neurological goal. If that wasn’t enough, pegcetacoplan is currently in phase 3 development for paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA) Although APLS faces strong competition, Kim sees « a top notch product profile in the pegcetacoplan, based on available data. » The analyst added, « With a potential PDUFA expected in mid-2021 for PNH, we believe investors remain focused on the considerations. potential commercial use for the primary indication of pegcetacoplanRegarding the GA opportunity, Kim said, “We underscored in our launch our appreciation for GA, which continues to be a potentially transformative catalyst for equities as you read the study (Q3 2021) With the DERBY and OAKS studies having completed their recruitment, we remain optimistic about pegcetacoplan’s positioning in AG, the clinical significance of the data currently available and the market opportunities. ”“ While long-term fundamentals remain strong and favorable, we continue to view SPLA as an underrated biotech follow-up asset for potential first approval in a well understood rare disease commercial market, a significant option in blockbuster indication geographic atrophy, and intriguing earlier – opportunities and strengths stage (C3G, COVID-19, gene therapy) We expect management to continue to achieve these goals, with a no new stock rating, ”Kim summed upEverything the SPLA did to convince Kim to maintain its outperformance (jee Buy) In addition to the call, it left the price target at $ 62, suggesting upside potential of 71% (To see Kim’s record, click here) What does the rest of the street have to say? 4 buys and 1 hold were issued in the past three months As a result APLS achieves a Strong Buy consensus rating Based on the $ 50 Average price target of 67, stocks could rise by 47% next year (See APLS stock market analysis on TipRanks) Boingo Wireless (WIFI) As for Boingo Wireless, it provides connectivity to mobile devices on small cell systems that encompass LTE as well as spectrum and Wi-Fi networks According to Oppenheimer, the Company’s future looks bright Representing the company, 5-star analyst Timothy Horan told clients that uncertainties over the pandemic and valuation prompted him to downgrade in April, but now he sees a attractive entry pointGiven that WIFI has strong assets in growing end markets (military and DAS), and the stock is trading at 13x Horan 2021 spot EBITDA, which is a 35% reduction from at a purchase price of 20x and reflects a 25% discount for tower companies at around 25x EBITDA 2021E, analyst believes an acquisition is likely “We think it’s highly likely that Boingo will sell some or all of its business to towers or a private equity focused firm. on infrastructure next year Strategic buyer could improve EBITDA by $ 15 million on unnecessary overhead alone In addition, there is a strong appetite for wireless infrastructure, as several recent transactions show, ”explained Horan Most likely, the business will split into three different companies, worth around $ 800 million on a SoTP basis compared to its current enterprise value of $ 500 million, according to Horan It also argues that the Military / Multi-Family segment has an enterprise value of $ 600 million based on an EBITDA multiple of 18x and its estimated EBITDA of $ 34 million, with DAS and Wholesale accounting for $ 200 million. additional in firm valueExplaining the military and DAS opportunity, Horan commented: “Positively, more 4G / 5G spectrum will be deployed and Boingo plans to commission a carrier for the first phase of LIRR by the end of 2020 Military sector demonstrated resilience during pandemic Boingo saw a sharp increase in traffic in Q2 2020 on military bases and is expanding higher 100Mbps ARPU service to more bases. « Further, Horan expects WIFI’s third quarter results are weak due to lower traffic at airports and venues, but believes revenue and cash EBITDA have likely bottomed as management pushes hard to cut expenses »We believe Boingo’s wireless assets are unique and the pandemic has highlighted the need for its critical neutral infrastructure to support connectivity. Recent acquisitions indicate strong interest in wireless infrastructure and Boingo’s valuation is attractive at current levels The military and DAS have been resilient and are well positioned for the long term, ”concluded HoranIn keeping with his bullish approach, Horan joined the Bulls, raising the rating from Performer to Outperforming and setting a price target of $ 15. Investors could pocket a 63% gain if this target is met within the next twelve months (To see Horan’s track record, click here) Do other analysts agree? They are Only buy notes, 7 to be exact, have been issued in the past three months So the message is clear: WIFI is a strong buy Considering the $ 19 average price target of 86, the stocks could climb 116% next year (See WIFI Stock Analysis on TipRanks) To find great ideas for stocks traded at attractive valuations, visit TipRanks Best Stocks To Buy, a newly launched tool that brings all of them together. TipRanks stock information Disclaimer: Opinions expressed in this article are those of featured analysts only Content is intended to be used for informational purposes only It is very important to do your own analysis before making any investment

Pfizer released superior third quarter results on Tuesday, but sales that missed views, and it said its key Covid-19 vaccine candidate is close to being fully recruited into clinical trials PFE slipped

Trading was based on a price between $ 131 and $ 134 for each Tiffany share, up from the previous price of $ 135 Last month, Tiffany sued the Louis Vuitton owner in a Delaware court, alleging the French company blocked the deal and improperly tried to renegotiate the deal. LVMH had counterattacked, alleging that the US company was mismanaged during the COVID-19 pandemic

GM-backed Lordstown Motors rallied to debut after electric truck maker completes merger with blank check company DiamondPeak

Earnings, Forecasts, Celanese, New York Stock Exchange, Carter’s, NYSE: CE, NYSE: CRI

World News – AU – RLI Corp Just Beat Expectations in revenue: Here’s what analysts think will happen next


Partagez avec vos proches


Donnez votre point de vue et aboonez-vous!


Votre point de vue compte, donnez votre avis

[maxbutton id= »1″]